A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).

被引：0
|
作者：
Townsend, A. R.
Pirc, L.
Hardingham, J.
Karapetis, C. S.
Tebbutt, N. C.
Singhal, N.
Price, T. J.
机构：
[1] Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Basil Hetzel Inst, Adelaide, SA, Australia
[3] Flinders Med Ctr, Adelaide, SA, Australia
[4] Austin Hosp, Ludwig Oncol Unit, Heidelberg, Vic 3084, Australia
[5] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[6] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS162
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Townsend, A.
    Tebbutt, N.
    Karapetis, C.
    Cooper, P.
    Singhal, N.
    Yeend, S.
    Pirc, L.
    Joshi, R.
    Price, T. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).
    Townsend, Amanda Rose
    Pirc, Louise
    Cooper, Pamela
    Tebbutt, Niall C.
    Karapetis, Christos Stelios
    Singhal, Nimit
    Price, Timothy Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
    Townsend, Amanda
    Tebbutt, Niall
    Karapetis, Christos
    Cooper, Pamela
    Singhal, Nimit
    Yeend, Susan
    Pirc, Louise
    Joshi, Rohit
    Hardingham, Jennifer
    Price, Timothy
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3838 - 3844
  • [4] A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
    Townsend, Amanda Rose
    Hardingham, Jennifer
    Tebbutt, Niall C.
    Karapetis, Christos Stelios
    Singhal, Nimit
    Joshi, Rohit
    Yeend, Sue
    Cooper, Pamela
    Dorward, Hilary
    Price, Timothy Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [5] A phase 1B study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Price, T. J.
    Pirc, L.
    Cooper, P.
    Tebbutt, N.
    Karapetis, C.
    Singhai, N.
    Townsend, A. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S549 - S549
  • [6] Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Reid, Tony R.
    Garrett, Christopher R.
    Beck, J. Thaddeus
    Davidson, Sheldon J.
    Mackenzie, Mary J.
    Brandt, Ulrike
    Rizvi, Syed
    Sharma, Sunil
    ANTICANCER RESEARCH, 2015, 35 (03) : 1567 - 1573
  • [7] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope Elizabeth
    Morse, Michael
    Blobe, Gerard C.
    Zafar, Yousuf
    Hsu, Shiaowen David
    Arrowood, Christy
    Ley, Sherri Ha
    Dropkin, Evan
    Niedzwiecki, Donna
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
    Shimoyama, Rai
    Kimura, Tetsuo
    Takaoka, Toshi
    Sakamoto, Kazuki
    Kawamoto, Shunji
    Yoshizaki, Koji
    Negoro, Yuji
    Goda, Fuminori
    Tsuji, Akihito
    Nakayama, Tsuyoshi
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    Niitsu, Yoshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Nagata, Naoki
    Maeda, Hiromichi
    Ishibashi, Keiichiro
    Hirata, Keiji
    Makiyama, Akitaka
    Iwamoto, Shigeyoshi
    Takemoto, Hiroyoshi
    Imasato, Mitsunobu
    Yoshida, Yoichiro
    Munemoto, Yoshinori
    Tanaka, Chihiro
    Morita, Yoshitaka
    Hotta, Yoshihiro
    Toyofuku, Atsushi
    Nagasaka, Takeshi
    Morita, Satoshi
    Sakamoto, Junichi
    Mishima, Hideyuki
    MEDICAL ONCOLOGY, 2019, 36 (06)
  • [10] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Naoki Nagata
    Hiromichi Maeda
    Keiichiro Ishibashi
    Keiji Hirata
    Akitaka Makiyama
    Shigeyoshi Iwamoto
    Hiroyoshi Takemoto
    Mitsunobu Imasato
    Yoichiro Yoshida
    Yoshinori Munemoto
    Chihiro Tanaka
    Yoshitaka Morita
    Yoshihiro Hotta
    Atsushi Toyofuku
    Takeshi Nagasaka
    Satoshi Morita
    Junichi Sakamoto
    Hideyuki Mishima
    Medical Oncology, 2019, 36
12345